 Double-Blind Method
"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 17 | 17 | | 1997 | 0 | 17 | 17 | | 1998 | 0 | 18 | 18 | | 1999 | 0 | 19 | 19 | | 2000 | 0 | 18 | 18 | | 2001 | 0 | 23 | 23 | | 2002 | 0 | 26 | 26 | | 2003 | 1 | 27 | 28 | | 2004 | 0 | 39 | 39 | | 2005 | 0 | 35 | 35 | | 2006 | 0 | 42 | 42 | | 2007 | 0 | 34 | 34 | | 2008 | 0 | 46 | 46 | | 2009 | 0 | 50 | 50 | | 2010 | 0 | 47 | 47 | | 2011 | 0 | 55 | 55 | | 2012 | 0 | 55 | 55 | | 2013 | 0 | 57 | 57 | | 2014 | 1 | 84 | 85 | | 2015 | 0 | 72 | 72 | | 2016 | 0 | 82 | 82 | | 2017 | 0 | 79 | 79 | | 2018 | 0 | 80 | 80 | | 2019 | 0 | 83 | 83 | | 2020 | 0 | 82 | 82 | | 2021 | 0 | 68 | 68 | | 2022 | 0 | 47 | 47 | | 2023 | 0 | 51 | 51 | | 2024 | 0 | 69 | 69 | | 2025 | 0 | 98 | 98 | | 2026 | 0 | 29 | 29 |
To return to the timeline, click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
van Baar MJB, Bjornstad P, Touw DJ, Joles JA, Krebber MM, Cherney DZI, van Raalte DH, Muskiet MHA. Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials. Nephrol Dial Transplant. 2026 Jul 31; 41(8):1520-1528.
-
Baker JV, Siegel LK, Losso MH, Vasudeva S, Nordwall JA, Harper K, Grund B, Havens JP, Fletcher CV, Fishchuk R, Kobrynska O, Abutidze A, Metchurtchlishvili R, Ginde AA, Aggarwal NR, Poulakou G, Mourad A, Gibbs KW, Saito S, Chayakulkeeree M, Mootsikapun P, Honda H, Mateu L, Gyrina O, Garcia A, Lee DG, Casey JD, Jain MK, Bengtson CD, Hite RD, Hiranburana N, Matthay MA, Arizmendez N, Nguyen HH, Drelick A, Mena Lora AJ, Parnia S, Trautner BW, Portsmouth SD, Shimizu R, Uehara T, Paredes R, Goodman AL, Vock DM, Gelijns AC, Weintrob AC, Bajema KL, Pett SL, Lundgren J, Schechner AJ, Higgs ES, Lane HC, Matthews GV, Self WH, Reilly C. Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial. Clin Infect Dis. 2026 Jul 23; 83(1):59-69.
-
Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, Mohamed Z, McCormack SE, Shoemaker AH, Kelsey MM, Ghalib L, Stalla G, Thaker VV, Habiby R, Ode KL, Wabitsch M, Dattani M, Abuzzahab MJ, Abdullatif H, Morgan R, Stefater-Richards M, Aroda VR, Friedrich C, Han JC, Ono H, Nagasaki K, Tanaka T, Isojima T, Arima H, Scimia C, Yuan G, Müller HL, Roth CL. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med. 2026 Jul 09; 395(2):138-150.
-
Erlandson KM, Gustafson L, Johnson JE, Kulik GL, Khuu V, Chahal N, Walpert AR, Galdamez ME, Zorgno I, Foldyna B, Jarraya M, Reusch JE, Lee H, Grinspoon SK, Jankowski CM, Fourman LT. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026 Jul 08; 16(7):e120740.
-
Knight EL, Nave G, Shaw SD, Apicella C, Bonin PL, Dreber A, Geniole SN, Johannesson M, Manfredi D, Mehta P, Proietti V, Stanton SJ, Luberti FR, Ortiz T, Carré JM. Does Testosterone Affect Cognitive Reflection? Evidence From a Double-Blind, Randomized Controlled Study of 1,000 Participants. Psychol Sci. 2026 Jul; 37(7):463-476.
-
Martens CR, Decker KP, DeConne TM, Sanjana F, Horvat F, Rizzi NA, Awad C, Habash E, Hobson JC, Kramer MK, Armstrong ML, Reisdorph N, Pohlig RT, Lanzi AM, Johnson CL, Cohen ML, Ellison JM. A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. Alzheimers Dement. 2026 Jul; 22(7):e71605.
-
Gonsalves NP, Dellon ES, Kliewer KL, Shoda T, Yearout R, Aceves SS, Arva NC, Besse JA, Caldwell JM, Chehade M, Coleman A, Collins MH, Anvari S, Falk GW, Gupta SK, Hiremath G, Katzka DA, Khoury P, Leung J, Menard-Katcher C, Menard-Katcher P, Peterson KA, Pletneva MA, Spergel AKR, Spergel JM, Vaysman T, Wechsler JB, Wright BL, Yang GY, Zhang X, Zhou M, Bansal A, Raphael BP, Radwan A, Maloney J, Martin A, Deniz Y, Furuta GT, Martin LJ, Rothenberg ME. Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2026 Aug; 11(8):672-688.
-
Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026 May 29; 41(6):1058-1068.
-
Steg PG, Goodman SG, Jukema JW, Martens P, Zirlik A, Bhatt DL, Menon V, Szarek M, Lesogor A, Stratz C, O'Donoghue F, Mena-Madrazo J, Shao Q, Liu K, Mehran R. Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. Am Heart J. 2026 Oct; 300:107493.
-
Bansal A, Stoffel EM, Lim R, Stanich PP, Patel SG, Burke CA, Hall MJ, Singh A, Boardman LA, Samadder NJ, Ballestar V, Muller C, Scott AJ, Benante KA, Xu Y, Eickhoff J, Hyun M, Zaborek J, Aquila L, Umar A, Szabo E, Della'Zanna G, Richmond E, Bengtson L, Schlom J, Donahue RN, Toney NJ, Horn LA, Palena C, Gulley JL, Samaddar S, Moore DF, Sharma P, Madan R, Hurley KE, Soon-Shiong P, Gabitzsch E, Sender L, Brenner D, Schuetze S, Djuric Z, Barroilhet LM, Thompson P, Bauman J, Khan SA, Vilar E. Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet). Front Immunol. 2026; 17:1809281.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|